Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Key Points

Key points are not available for this paper at this time.

Abstract

ClinicalTrials.gov, NCT02447003.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper

Cite This Study

Adams et al. (Thu,) studied this question.

synapsesocial.com/papers/69d8d15017a1cc0598d18a0d https://doi.org/https://doi.org/10.1093/annonc/mdy517

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1<i>In Situ</i> Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas2014 · 444 citations
2

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1<i>In Situ</i> Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas2014 · 444 citations
2

Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086

2017 · 186 citations

3The blockade of immune checkpoints in cancer immunotherapy2012 · 13,758 citations

4Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer2018 · 71 citations

5Time for more optimism in metastatic breast cancer?2013 · 69 citations